Free Trial
NYSE:HUM

Humana (HUM) Stock Price, News & Analysis

$357.86
-7.28 (-1.99%)
(As of 09/6/2024 ET)
Today's Range
$357.18
$369.17
50-Day Range
$345.56
$404.52
52-Week Range
$298.61
$530.54
Volume
1.08 million shs
Average Volume
1.63 million shs
Market Capitalization
$43.12 billion
P/E Ratio
22.28
Dividend Yield
0.99%
Price Target
$398.70

Humana MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
11.4% Upside
$398.70 Price Target
Short Interest
Healthy
1.87% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.81mentions of Humana in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
22.43%
From $16.14 to $19.76 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

28th out of 910 stocks

Hospital & Medical Service Plans Industry

2nd out of 11 stocks

HUM stock logo

About Humana Stock (NYSE:HUM)

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

HUM Stock Price History

HUM Stock News Headlines

Stethoscope and digital tablet — Photo
Tenet Healthcare Stock Sees Strong Gains from Acute Care Boom (HUM)
Hospital and ambulatory care operator Tenet Healthcare Co. (NYSE: THC) is operating in the sweet spot of healthcare these days.
hospital beds and equipment
Medical Technology Stock Benefits from Rising Acute Care Demand (HUM)
Medical and surgical products manufacturer Stryker Co. (NYSE: SYK) is a beneficiary of the acute care boom occurring in the healthcare industry.
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Humana (NYSE:HUM) PT Raised to $400.00 at Royal Bank of Canada
Humana extends gains as inpatient activity meets expectations
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Wells Fargo Remains a Buy on Humana (HUM)
Here's Why Humana (HUM) Rebounded in Q2
See More Headlines
Receive HUM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 7/26 Dividend
6/28/2024
Dividend Payable
7/26/2024
Last Earnings
7/31/2024
Today
9/07/2024
Ex-Dividend for 10/25 Dividend
9/30/2024
Dividend Payable
10/25/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Hospital & medical service plans
Sub-Industry
Managed Health Care
CUSIP
44485910
Employees
67,600
Year Founded
1961

Price Target and Rating

Average Stock Price Target
$398.70
High Stock Price Target
$579.00
Low Stock Price Target
$310.00
Potential Upside/Downside
+11.4%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
21 Analysts

Profitability

Net Income
$2.49 billion
Pretax Margin
2.18%

Debt

Sales & Book Value

Annual Sales
$112.04 billion
Cash Flow
$34.61 per share
Book Value
$138.93 per share

Miscellaneous

Free Float
120,115,000
Market Cap
$43.12 billion
Optionable
Optionable
Beta
0.51

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Should I Buy Humana Stock? HUM Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Humana Inc.:

  • Humana Inc. stock price is currently at $358.55, showing a positive trend in recent trading.
  • Analysts have set a consensus price target of $396.35, indicating potential for growth.
  • Fifth Third Bancorp increased its holdings in Humana by 41.7% in the second quarter, reflecting confidence in the company.
  • Recent analyst reports have upgraded Humana to "hold" and "buy" ratings, suggesting positive sentiment.
  • Institutional investors and hedge funds continue to show interest in Humana, with significant stakes in the company.

Cons

Investors should be bearish about investing in Humana Inc. for these reasons:

  • Humana's P/E ratio of 22.33 may indicate the stock is currently overvalued.
  • The company's beta of 0.51 suggests lower volatility compared to the market average, potentially limiting short-term gains.
  • While some analysts have upgraded Humana, others have maintained a "neutral" rating, indicating mixed opinions on the stock.
  • Debt-to-equity ratio of 0.70 may raise concerns about the company's financial leverage.
  • Despite recent positive movements, Humana's stock has faced resistance at certain price levels, signaling potential challenges ahead.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 27, 2024. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

HUM Stock Analysis - Frequently Asked Questions

How have HUM shares performed this year?

Humana's stock was trading at $457.81 at the beginning of 2024. Since then, HUM shares have decreased by 21.8% and is now trading at $357.86.
View the best growth stocks for 2024 here
.

How were Humana's earnings last quarter?

Humana Inc. (NYSE:HUM) issued its earnings results on Wednesday, July, 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping analysts' consensus estimates of $5.89 by $1.07. The firm's quarterly revenue was up 10.4% on a year-over-year basis.
Read the conference call transcript
.

What is Bruce D. Broussard's approval rating as Humana's CEO?

1,597 employees have rated Humana Chief Executive Officer Bruce D. Broussard on Glassdoor.com. Bruce D. Broussard has an approval rating of 87% among the company's employees.

Does Humana have any subsidiaries?

Humana subsidiaries include Enclara Healthcare, Kindred Healthcare, American Eldercare, FPG, Metropolitan Health Networks, Certify Data Systems, Harris Rothenberg International, and more.

Who are Humana's major shareholders?

Humana's top institutional shareholders include Pzena Investment Management LLC (1.92%), Davis Selected Advisers (1.92%), Marshall Wace LLP (1.18%) and Legal & General Group Plc (0.98%). Insiders that own company stock include Bruce D Broussard, David A Jr/Ky Jones, Samir Deshpande, Timothy S Huval, Joseph C Ventura, Susan M Diamond, Jorge S Mesquita and William Kevin Fleming.
View institutional ownership trends
.

How do I buy shares of Humana?

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA) and Boeing (BA).

This page (NYSE:HUM) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners